| 0.4351 -0.036 (-7.64%) | 11-28 13:35 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.91  |
1-year : | 1.16 |
| Resists | First : | 0.78 |
Second : | 0.99 |
| Pivot price | 0.53 |
|||
| Supports | First : | 0.43 |
Second : | 0.35 |
| MAs | MA(5) : | 0.48 |
MA(20) : | 0.53 |
| MA(100) : | 0.82 |
MA(250) : | 4.5 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.3 |
D(3) : | 3.6 |
| RSI | RSI(14): 38.2 |
|||
| 52-week | High : | 13.19 | Low : | 0.43 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BBLG ] has closed above bottom band by 19.1%. Bollinger Bands are 0.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.49 - 0.5 | 0.5 - 0.5 |
| Low: | 0.45 - 0.46 | 0.46 - 0.46 |
| Close: | 0.47 - 0.47 | 0.47 - 0.48 |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Fri, 17 Nov 2023
Financings for Nov. 17, 2023 - BioWorld Online
Fri, 17 Nov 2023
US Stocks Edge Lower; Housing Starts Rise In October - Bone Biologics (NASDAQ:BBLG), ChargePoint Hldgs (N - Benzinga
Thu, 16 Nov 2023
Should You Buy Bone Biologics Corp (BBLG) Stock After it Is Higher By 67.92% in a Week? - InvestorsObserver
Thu, 16 Nov 2023
Why Is Augmedix (AUGX) Stock Down 27% Today? - InvestorPlace
Tue, 26 Sep 2023
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device - BioSpace
Tue, 11 Jul 2023
Top Penny Stocks Today? Why ELOX Stock Is Skyrocketing & 3 More To Watch - Penny Stocks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Devices
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 13.6 (%) |
| Held by Institutions | 3.2 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 15 (K) |
| EPS | -1.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -117.4 % |
| Return on Equity (ttm) | -158.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.27 |
| PEG Ratio | 0 |
| Price to Book value | 0.36 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|